T1	Participants 39 80	homozygous familial hypercholesterolaemia
T2	Participants 163 204	Homozygous familial hypercholesterolaemia
T3	Participants 789 863	ten countries in North America, Europe, the Middle East, and South Africa.
T4	Participants 864 1215	50 eligible patients (aged â‰¥12 years) with homozygous familial hypercholesterolaemia, on stable lipid-regulating therapy for at least 4 weeks, and not receiving lipoprotein apheresis, were randomly allocated by a computer-generated randomisation sequence in a 2:1 ratio to receive subcutaneous evolocumab 420 mg or placebo every 4 weeks for 12 weeks
T5	Participants 1368 1375	system.
T6	Participants 1376 1594	Patients, study personnel, and the funder were masked to treatment and to the efficacy results by the central laboratory not returning LDL cholesterol or any lipid results to the clinical sites after the baseline visit
T7	Participants 1840 2028	the 50 eligible patients randomly assigned to the two treatment groups, 49 actually received the study drug and completed the study (16 in the placebo group and 33 in the evolocumab group)
T8	Participants 2454 2527	INTERPRETATION In patients with homozygous familial hypercholesterolaemia
